Table 1.

Patient demographics for AECA ELISA categories

ELISA Categories	Negative (n=40)	Intermediate (n=20)	P Value	Strongly Positive (n=36)	P Value
ELISA values, mean; median
Endoglin	1058; 992	6486; 6357	<0.001	37,432; 26,101	<0.001
FLT3	1311; 1105	5499; 5876	<0.001	29,876; 19,104	<0.001
EDIL3	324; 0	4437; 4397	<0.001	34,213; 23,290	<0.001
ICAM4	3215; 3272	15,378; 13,077	<0.001	56,839; 32,896	<0.001
Recipient age (yr), mean±SD	52±16	49±13	0.47	47±15	0.22
Race, % not white	40	40	>0.99	50	0.49
Men, %	25	50	0.08	44	0.09
Previous transplantation, %	40	50	0.58	39	>0.99
HLA sensitization,a %	90	90	>0.99	97	0.36
Mean CPRAb (CDC-XM, FCXM), %	27, 37	27, 38	0.94	35, 44	0.48
Original ABO or HLA barrier,c %
ABOi	10	15	0.68	18	0.50
CDC-XM+	2	0	>0.99	6	0.60
FCXM+	15	15	>0.99	19	0.76
FCXM−, DSA+	48	55	0.78	50	>0.99
No DSA	35	30	0.78	25	0.45
Donor, mean age (yr)±SD	38±13	43±12	0.12	42±16	0.25
Live donor, %	45	55		42
Deceased donor, %	55	45	0.59	58	0.82
HLA-A;B;DR;DQ mismatch, mean±SD	4.7±2.3	4.1±2.7	0.41	5.2±1.5	0.21
Plasmapheresis treatments
No pre- or post-treatments, %	50	35	0.41	42	0.50
Pretransplant, mean, median	1.0, 0.0	1, 1	0.67	0.5, 0.0	0.17
Post-transplant, mean, median	3.6, 1.0	3, 2	0.86	4.5, 2.0	0.54
Anti-CD25 induction, %	17	20	>0.99	15	0.76
Thymoglobulin induction, %	83	80	>0.99	85	0.76
Rituximab induction, %	33	45	0.40	38	0.63

CPRA, calculated panel reactive antibody; CDC-XM, cytotoxicity crossmatch; ABO, blood group antigen; ABOi, blood group incompatible; DSA, donor HLA-specific antibody; HLA-A;B;DR;DQ, histocompatibility antigens.

^aHLA-specific antibody detected on Luminex bead immunoassays.

^bCPRA was determined for HLA antibodies of sufficient strength to yield a positive CDC-XM or FCXM.

^cOriginal donor HLA-specific antibody (DSA) strength before desensitization treatment.